Preclinical and clinical studies demonstrate GLP-1 RAs’ cardioprotective effects, efficacy in hypertension and dyslipidemia, substantial weight loss in diabetes and obesity, and neuroprotective roles in stroke and neurodegenerative diseases. This evidence concerns the gene GCG and diabetes mellitus.